Skip to main content

Table 1 Descriptive characteristics and bloodborne data of pre-diabetic subjects before and after an eight week intervention of ALCA or placebo

From: Effect of oral acetyl L-carnitine arginate on resting and postprandial blood biomarkers in pre-diabetics

Variable

Pre Intervention ALCA

Post Intervention ALCA

Pre Intervention Placebo

Post Intervention Placebo

Age (yrs)

31 ± 3

31 ± 3

35 ± 3

35 ± 3

Height (cm)

172 ± 3

172 ± 3

169 ± 3

169 ± 3

Weight (kg)

85 ± 4

83 ± 5

91 ± 5

90 ± 4

BMI (kg·m-2)

28.5 ± 1.9

27.8 ± 1.7

31.7 ± 2.1

32.6 ± 2.4

Body Fat (%)

28 ± 2

26 ± 3

28 ± 2

27 ± 2

Waist (cm)

94 ± 4

92 ± 4

101 ± 5

100 ± 5

Hip (cm)

109 ± 4

106 ± 4

113 ± 5

111 ± 6

Waist:Hip

0.87 ± 0.05

0.87 ± 0.03

0.89 ± 0.04

0.90 ± 0.05

Resting HR (bpm)

73 ± 2

71 ± 2

73 ± 2

72 ± 3

Resting SBP (mmHg)

123 ± 1

121 ± 1

119 ± 1

118 ± 2

Resting DBP (mmHg)

79 ± 1

78 ± 1

80 ± 1

80 ± 1

Glucose (mg·dL-1)

109 ± 5

103 ± 5

112 ± 6

111 ± 5

HbA1c (%)

6.6 ± 1.9

6.2 ± 2.2

6.7 ± 1.8

6.6 ± 2.2

Insulin (μU·mL-1)

12.1 ± 1.8

11.4 ± 2.1

12.4 ± 1.9

12.7 ± 2.0

HOMA-IR

3.3 ± 1.3

2.9 ± 1.2

3.4 ± 1.4

3.5 ± 1.6

Total Cholesterol (mg·dL-1)

195 ± 13

192 ± 14

184 ± 14

179 ± 15

HDL-C (mg·dL-1)

51 ± 7

48 ± 6

47 ± 4

50 ± 5

LDL-C (mg·dL-1)

127 ± 13

132 ± 11

123 ± 8

117 ± 10

CRP (ng·mL-1)

1432 ± 342

1389 ± 328

1652 ± 408

1738 ± 425

  1. Data are mean ± SEM.
  2. No statistically significant differences noted (p > 0.05).